PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(04): 481-483
DOI: 10.4103/ijmpo.ijmpo_101_18
Original Article

Required Treatment Expenditures for Hepatitis C Virus Infection and Advantage in the Reduction of Hepatocellular Carcinoma Incidence: Analysis of Possible Options in an Endemic Area

Beuy Joob
Sanitation 1 Medical Academic Center, Bangkok, Thailand
,
Viroj Wiwanitkit
Department of Community Medicine, Dr. DY Patil University, Pune, Maharashtra, India
Department of Tropicla Medicine, Hainan Medical University, Haikou, China
Department of Medical Science, Faculty of Medicine, University of Nis, Niš, Serbia
› Institutsangaben Financial support and sponsorship Nil.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Background: Hepatitis C virus (HCV) infection is a known underlying factor contributing to hepatocellular carcinogenesis. The use of direct-acting antiviral (DAA) medication is a form of clinical management for controlling HCV infection and reducing the hepatocellular carcinoma incidence. This medication is introduced to several endemic areas. The big concern is on the treatment expenditures. Several alternative options are proposed and it is required to assess the effect of each alternative option. Objective: Here, the authors assessed and estimated the required treatment expenditures for HCV infection and advantage in the reduction of hepatocellular carcinoma incidence based on the analysis of possible options in an endemic area. Methods: A medical economics analysis was done. Results: According to the cost–utility analysis, the best alternative option that is hereby recommended is DAA medication coverage for all cases. Conclusion: DAA medication coverage for all cases is recommended.

Keywords

Expenditure - hepatitis C - incidence - infection - treatment


Publikationsverlauf

Eingereicht: 02. Mai 2018

Angenommen: 21. Mai 2018

Artikel online veröffentlicht:
03. Juni 2021

© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Puchades Renau L, Berenguer M. Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies. Hemodial Int 2018; 22 (01) Suppl S8-21
    CrossrefPubMedGoogle Scholar
  • 2 Braillon A. Direct-acting antiviral drugs and hepatitis C virus: A therapeutic revolution?. Cancer 2015; 121: 4268-9
    CrossrefPubMedGoogle Scholar
  • 3 Roche B, Coilly A, Duclos-Vallee JC, Samuel D. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC. Liver Int 2018; 38 (01) Suppl 139-45
    CrossrefPubMedGoogle Scholar
  • 4 Wasitthankasem R, Vichaiwattana P, Siripon N, Posuwan N, Auphimai C, Klinfueng S. et al. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study. PLoS One 2018; 13: e0196301
    CrossrefPubMedGoogle Scholar
  • 5 Poovorawan K, Pan-Ngum W, White LJ, Soonthornworasiri N, Wilairatana P, Wasitthankasem R. et al. Estimating the impact of expanding treatment coverage and allocation strategies for chronic hepatitis C in a direct antiviral agent era. PLoS One 2016; 11: e0163095
    CrossrefPubMedGoogle Scholar
  • 6 Duberg AS, Blach S, Falconer K, Kåberg M, Razavi H, Aleman S. et al. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scand J Gastroenterol 2015; 50: 233-44
    CrossrefPubMedGoogle Scholar
  • 7 Chhatwal J, He T, Lopez-Olivo MA. Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antivirals. Pharmacoeconomics 2016; 34: 551-67
    CrossrefPubMedGoogle Scholar